Aspects of Monitoring Clinical Trials in the Era of Immunotherapy

The recent events in immunooncology have forced us to adapt at speed not seen before all our internal processes from study design to monitoring and data management. A lot of lessons learned, at all levels in processes, systems, resources and people! It has not been easy as some of the old approaches to clinical trials didn’t fit the needs of the new studies. The ride these past 3 years, has enabled us to become more flexible, faster and adaptive to new developmental approaches and more importantly, have made possible to deliver faster to patients some of the best innovations we will witness for many years.